Abstract | For a long time, lysosomes were considered merely to be cellular incinerators involved in the degradation and recycling of cellular waste. However, now there is compelling evidence indicating that lysosomes have a much broader function and that they are involved in fundamental processes such as secretion, plasma membrane repair, signalling and energy metabolism. Furthermore, the essential role of lysosomes in autophagic pathways puts these organelles at the crossroads of several cellular processes, with significant implications for health and disease. The identification of a master regulator, transcription factor EB (TFEB), that regulates lysosomal biogenesis and autophagy has revealed how the lysosome adapts to environmental cues, such as starvation, and targeting TFEB may provide a novel therapeutic strategy for modulating lysosomal function in human disease.
Lysosomes are membrane-bound organelles that were first described in 1955 by Christian de Duve 1 . They have an acidic lumen, which is limited by a single-lipid bilayer membrane and contains several types of hydrolases that are devoted to the degradation of specific substrates. The lysosomal membrane contains proteins that are involved in the transport of substances into and out of the lumen, acidification of the lyso somal lumen and fusion of the lysosome with other cell ular structures 2 . Extracellular material that is destined for degradation reaches the lysosome mainly through the endocytic pathway 3 , whereas intra cellular components are transported to the lysosome by autophagy [4] [5] [6] . Lysosomes can also secrete their contents by fusing with the plasma membrane 7, 8 . This process, which is known as lysosomal exocytosis, is very active in particular cell types, such as cells from the haematopoietic lineage 9 , osteoclasts 10 and melanocytes 11 . In addition to cellular clearance and secretion, the lysosome mediates a range of biological processes, such as plasma membrane repair, cell homeostasis, energy metabolism and the immune response. Little is known about how lysosomal function varies in different cells, tissues, life stages and individuals, as well as under differ ent physio logical conditions. However, in recent years, the static view of the lysosome has progressively changed into a much broader and dynamic perspective. The ability of the lysosome to adapt to different environmental cues became evident with the discovery that lysosomal biogenesis and function are subject to global transcriptional regulation. This novel concept of 'lysosomal adaptation' is important for our understanding of how basic biological processes, ranging from cellular clearance to the control of energy metabolism, respond to environmental cues.
In this Review, we first describe the structure of the lysosome and its established role in cellular clearance. We then consider the emerging roles of lyso somes, including their function in nutrient sensing and signalling, before discussing the identification of the transcription factor EB (TFEB) as a key protein that regulates lysosomal biogenesis and autophagy 12, 13 . Finally, we focus on how lysosomal dysfunction leads to human disease.
Lysosome structure
The complex series of events leading to the formation of a mature lysosome has been described in recent articles 2, [14] [15] [16] [17] [18] [19] [20] [21] . The mature lysosome has an acidic lumen encircled by a cholesterol-poor membrane 22 
. The main function of the lysosomal membrane is to segregate the aggressive acidic environment of the lumen from the rest of the cell. This is ensured by the presence of a thick glycocalyx that lines the internal perimeter to prevent the lysosomal membrane being degraded by luminal acid hydrolases. The lysosomal membrane also actively mediates the fusion of lysosomes
Glycocalyx
The polysaccharide-based coating on the inner side of a lysosomal membrane that protects this organelle from digestion by lysosomal enzymes.
Signals from the lysosome: a control centre for cellular clearance and energy metabolism Carmine Settembre [1] [2] [3] [4] with other cellular structures, such as late endosomes, autophagosome s and the plasma membrane, as well as the transport of metabolites, ions and soluble substrates into and out of lysosomes.
Lysosomal trafficking and fusion are mediate d by specific sets of membrane-associated RAB GTPases 17, 18, 23, 24 and SNARE proteins [25] [26] [27] . Of note, the ability of minimal 'synthetic' endosomes to fuse in vitro with purified early endosomes or with each other was reconstituted by using 17 recombinant human proteins, including specific RAB GTPases and SNAREs 28 . RAB5 and RAB7 are specifically involved in the tethering and docking processes in endolysosomal membrane traffick ing pathways 23, 24 . Furthermore, a reduction in RAB5 levels decreases the number of endosomes and lysosomes and blocks endocytosis 29 . A specific combinatorial set of SNAREs, including vesicle-associated membrane protein 7 (VAMP7), VAMP8, VTI1B, syntaxin 7 and syntaxin 8, forms the trans-complexes that drive lysosom e-endosome fusion and the homotypic fusion between endosomes 25 . Interestingly, recent studies revealed that SNAREs that are involved in the fusion between autophagosomes and endolysosomal vesicles, such as syntaxin 17, also participate in autophagosome biogenesis 30, 31 . The lysosomal lumen contains approximately 60 different soluble hydrolases, which are active at acidic pH. These enzymes are the main players in the execution of multistep catabolic processes. They include members of protein families such as the sulphatases, glycosidases, peptidases, phosphatases, lipases and nucleases, which allow the lysosome to hydrolyse a vast repertoire of biological substrates, including glycosaminoglycans, sphingolipids, glycogen and proteins. The targeting of most lysosomal enzymes to lysosomes, as well as their ability to be secreted and taken up again by cells, is mediated by a mannose-6-phosphate modification that they undergo in the late Golgi compartments 14, 32 . The ability of cells to take up lysosomal enzymes via the mannose-6-phosphate receptor (MPR) is the basis for enzyme replacement therapy for several lysosomal storage diseases (LSDs) 33 . A different targeting mechanism, which is mediated in part by the lysosomal receptor LIMP2 (lysosome integral membrane protein 2; also known as SCARB2), was recently identified for β-glucocerebrosidase 34 .
Box 1 | The structure of the lysosome
Lysosomes have a limiting membrane, which is composed of a single-lipid bilayer and integral and peripheral proteins, and an acidic lumen that contains soluble hydrolytic enzymes and activators [47] [48] [49] 194, 195 . A glycocalyx lines the internal lysosomal perimeter, protecting the membrane from the acidic environment of the lumen. Soluble enzymes are directly involved in the degradation of metabolites, whereas the lysosomal membrane segregates this catalytic potential and also actively participates in the maintenance of plasma membrane integrity, the establishment of the acidic pH of the lysosomal lumen, metabolite and ion transport, lysosomal trafficking and catalysis. Some key functional categories of lysosomal membrane proteins are shown (see the figure). Trafficking and fusion machinery proteins comprise SNAREs and RABs. Structural proteins include lysosome-associated membrane protein 1 (LAMP1), which is the most abundant lysosomal membrane protein accounting for 50% of total protein in this membrane. LAMP1 is mainly involved in lysosomal trafficking by mediating the attachment of lysosomes to the transport machinery 2, 196 . The lysosomal nutrient sensing (LYNUS) machinery includes several protein complexes that interact on the lysosomal surface, and its role is to sense the nutrient content of the lysosome and signal the information to the nucleus (see main text). An important component of the LYNUS machinery is the vacuolar ATPase (v-ATPase), a large multimeric channel that uses the energy derived from ATP hydrolysis to transport protons across the lysosomal membrane in order to generate the acidic pH of the lysosomal lumen 197, 198 . Several ion channels have been identified on the lysosomal membrane. The transient receptor potential (TRP) family member mucolipin 1 (MCOLN1) is a non-selective cation channel 199 that is involved in Ca 2+ signalling during lysosomal fusion with other membranes, such as the plasma membrane [85] [86] [87] and autophagosomes 200 . A deficiency in MCOLN1 causes mucolipidosis type IV, a lysosomal storage disease 201, 202 . CIC7, a Cl -channel, contributes to lysosomal acidification and is involved in inherited osteopetrosis 60, 61, 203 . Transporters in the lysosomal membrane include LAMP2A, which mediates chaperone-mediated autophagy by binding cytosolic protein substrates on the lysosomal membrane so that they can be internalized and degraded 5, 204 . Mutations of LAMP2A cause Danon disease, which is associated with the accumulation of autophagic vacuoles in muscle cells 205 . Niemann-Pick C1 protein 1 (NPC1) is a lysosomal membrane protein involved in the export of cholesterol from the endolysosomal compartment, and it is mutated in Niemann-Pick disease type C1 (REF. 206 ). The recently identified lysosomal amino acid transporter 1 (LAAT1) is involved in the transport of Lys and Arg across the lysosomal membrane and into the lysosome, and it has a crucial role in cellular amino acid homeostasis 207 . Enzymes on the lysosomal membrane include heparan-α glucosaminide N-acetyltransferase (HGSNAT). This enzyme participates in the stepwise degradation of heparan sulphate [208] [209] [210] , and mutation of this protein causes mucopoly saccharidosis type IIIC. PSAP, prostate-specific acid phosphatase. Nature Reviews | Molecular Cell Biology The selective degradation of intra-lumenal membranes and lipids within lysosomes occurs in specialized intra-lysosomal vesicles. These vesicles contain a complex machinery composed of proteins that are involved in lipid degradation, such as water-soluble acid hydrolases and sphingolipid activator proteins (SAPs) [35] [36] [37] [38] [39] . Studying glycosphingolipid catabolism in patients with defects in this process was instrumental for the understandin g of this complex pathway [40] [41] [42] . Importantly, a number of non-lysosomal proteins modulate the functions of lysosome-resident proteins. Prominent examples of these are the two different types of MPRs, cation-independent MPR (CI-MPR) and cation-dependent MPR (CD-MPR), which dynamically shuttle between the trans-Golgi network (TGN) and late endosomes and are involved in the targeting of lysosomal enzymes to the lysosome 32 . Another example is sulphatase-modifying factor 1 (SUMF1), an endoplasmic reticulum (ER)-resident protein that is responsible for a post-translational modification (PTM), the conversion of a highly conserved Cys in the active site to α-formylglycine, which is required for the activation of all sulphatases 43, 44 . Various methods have been used to purify lyso somes and analyse their proteome [45] [46] [47] [48] [49] . Some of these approaches are based on subcellular fractionations, whereas others are based on specific features of soluble lysosomal proteins, such as the mannose-6-phosphate modification of their carbohydrate moieties 49 . In these efforts, it has been difficult to distinguish between lysosome-resident proteins, which are constituents of the lyso somal machinery, and proteins that are delivered to the lysosome for degradation. Therefore, we are still far from the identification and functional characterization of all lysosomal proteins. On the basis of current data, a little over 100 bona fide lysosome-resident proteins have been identified; ~70 of these are lysosomal matrix proteins and ~50 are lysosomal membrane proteins 48 . However, these numbers are likely to increase in the near future.
Lysosome functions
Lysosomal functions can be schematically divided into three main types: degradation, secretion and signalling (FIG. 1) .
Lysosome-mediated degradation. Similar to the transport of urban waste to incinerators, the collection and transport of cellular waste to lysosomes requires complex logistics. The cell has developed different routes for transporting extracellular and intracellular waste to the lysosome. Extracellular material reaches the lysosome mainly through endocytosis. The capture of extracellular material and integral membrane proteins occurs through specific endocytic mechanisms according to the nature of the cargo. Prominent examples of endocytosis are phagocytosis, macropinocytosis, clathrin-mediated endocytosis, caveolin-mediated endocytosis and clathrinand caveolin-independent endocytosis 50 . Signalling receptors may undergo endocytosis through clathrinmediated endocytosis 51 or clathrin-independent mechanisms 52 . After internalization, the receptors are routed to early endosomes 53 . From the endosomes, the receptors can either be recycled back to the plasma membrane to allow for repeated receptor activation or be sorted and targeted for lysosomal degradation, resulting in the termin ation of receptor signalling [54] [55] [56] . A known hallmark of endosome-to-lysosome maturation is the progressive decrease of the internal pH to ~pH 5 in the mature lysosome 57 . This is crucial for the uptake of acid hydrolases by MPRs into the endosomal lumen and the recycling of receptors back to the Golgi network 15 . The generation and maintenance of the lysosomal pH gradient requires the activity of a protonpumping v-type ATPase, which uses the energy of ATP hydrolysis to pump protons into the lysosomal lumen 58 . Additional lysosomal membrane channels are thought to be involved in lysosomal acidification, such as the anion transporter chloride channel 7 (ClC7) [59] [60] [61] [62] and the catio n transporters mucolipin 1 (MCOLN1; also known as TRPML1) and two pore calcium chann el 1 (TPC1) and TCP2 (REF. 62 ), which mediate Ca 2+ and Na + release from the lysosome [62] [63] [64] [65] 106 . However, the role of each of these channels and the precise mechanisms underlying the complex regulation of lysosomal acidification and ion balance are still controversial and require further investigation.
Intracellular materials reach the lysosome through the process of autophagy, a self-eating catabolic pathway that is used by cells to capture their own cytoplasmic components destined for degradation and recycling. Three types of autophagy have been identified: microautophagy; chaperone-mediated autophagy (CMA); and macroautophagy. During microautophagy, cytosolic Lysosomes are involved in the degradation and recycling of intracellular material (via autophagy) and extracellular material (via endocytosis). In these processes, lysosomes fuse with autophagosomes and with late endosomes, respectively. The resulting breakdown products are used to generate new cellular components and energy in response to the nutritional needs of the cell. Lysosomes also undergo Ca 2+ regulated exocytosis to secrete their content into the extracellular space and to repair damaged plasma membranes. Upon plasma membrane injury, lysosomes rapidly migrate to the damaged site and fuse with the plasma membrane to allow efficient resealing. More recently, lysosomes have been identified as signalling organelles that can sense nutrient availability and activate a lysosome-to-nucleus signalling pathway that mediates the starvation response and regulates energy metabolism.
Lysosome-related organelles
(LROs). Cell type-specific compartments that include melanosomes, lytic granules, major histocompatibility complex class II compartments, platelet-dense granules, basophil granules, azurophil granules and Drosophila melanogaster pigment granules.
proteins are engulfed in the lysosome through the direct invagination of lysosomal or endosomal membranes 6, 66, 67 . In CMA, cytosolic proteins are transported into the lysosomal lumen through chaperone-and receptor-mediated internalization, which requires the unfolding of proteins and their translocation via lysosome-associated membrane protein 2A (LAMP2A) 5, 68, 69 . Macroautophagy, herein referred to as autophagy, relies on the bio genesis of autophagosomes, which are double membrane-bound vesicles that sequester cytoplasmic material and then fuse with lysosomes. Thus, the role of all three types of autophagy in degradation and recycling processes is strictly dependent on lysosomal function.
Autophagy is activated by a broad range of cellular stress-inducing conditions and it mediates the degradation of protein aggregates, oxidized lipids, damaged organelles and intracellular pathogens. The resulting breakdown products are used to generate new cellular components and energy in response to the nutritional needs of the cell. The mechanisms underlying autophagy and its relevance both in health and disease have been extensively studied in the past decade and comprehensivel y described in recent reviews 70, 71 .
Lysosomal exocytosis. Lysosomes can secrete their content through a process called lysosomal exocytosis, which can be detected by the translocation of lysosomal membrane marker proteins (for example, LAMP1) to the plasma membrane 7, 8, 72 . In this process, lysosomes fuse with the plasma membrane through a Ca 2+ -regulated mechanism that leads to a bulk release of the lyso somal content into the extracellular matrix [72] [73] [74] [75] [76] [77] . Initially, lyso somal exocytosis was thought to be limited to professional secretory cells that contain a subset of specialized lysosome-related organelle s (LROs) 75 , but soon it was shown that any cell type can perform this function 72 . Lysosomal exocytosi s mediates several physiological processes, such as degranulation in cytotoxic T lymphocytes 78 , bone resorption by osteoclasts 10 , parasite defence by mast cells and eosinophi ls 79, 80 , melanocyte function in pigmentation 11 , platele t function in coagulation 81 and hydrolase release by spermato zoa during fertilization 82 . The molecular machinery mediating Ca 2+ -regulated exocytosis of conventional lysosomes includes the vesicle SNARE (v-SNARE) VAMP7, the Ca 2+ senso r synapto tagmin VII (SYTVII) on lysosomes, the target SNAREs (t-SNAREs) SNAP23 and syntaxin 4 on the plasma membrane 83 and several RAB proteins on the lysosomal surface 8, 27, 83, 84 . Another important mediator of lyso somal exocytosis is the lysosomal membrane Ca 2+ channe l MCOLN1 . It was also postulated that autophagy proteins may regulate lysosomal exo cytosis. For example, lipidation of the late autophagosome marker LC3 is required for the secretion of lysosomal contents into the extracellular space, as this directs the lysosomes to fuse with the plasma membrane [88] [89] [90] . However, autophagosomes may not be mediating this process 89 . Lysosomal exocytosis is not only responsible for the secretion of lysosomal content, it also has a crucial role in plasma membrane repair. Plasma membrane injuries induce the rapid migration of lysosomes to the damaged site. Lysosomes then fuse to the plasma membrane and efficiently reseal the damaged sites 91, 92 . This process is also important in defence mechanisms against bacterial infection 93 and has been implicated in a specific type of muscular dystrophy, which is characterized by a defect in muscle fibre repair 94 . Lysosomal exocytosis is transcriptionally regulated by TFEB, a master regulator of lysosomal biogenesis (see below). TFEB induces both the docking and fusion of lysosomes with the plasma membrane by regu lating the expression of certain genes, the protein products of which increase lysosomal dynamics and cause a MCOLN1-mediated increase in intracellular Ca 2+ (REF. 86 ). Interestingly, TFEB-mediated regulation of lysosomal exocytosis has an important role in osteoclast differentiation and bone resorption 95 .
Signalling from lysosomes. It has become evident that the lysosome plays an important part in nutrient sensing and in signalling pathways that are involved in cell metabolism and growth. Remarkably, the kinase complex mammalian target of rapamycin complex 1 (mTORC1), a master controller of cell and organism growth 96 , exerts its activity on the lysosomal surface 97 . The lysosomal localization of mTORC1 suggests a mechanistic co-regulation between cell growth and cell catabolism. Growth factors, hormones, amino acids, glucose, oxygen and stress are the major activators of mTORC1, which in turn positively regulates proteins, mRNAs, lipid biosynthesis and ATP production 96, 98 . In this way, mTORC1 regulates the balance between biosynthetic and catabolic states. When nutrients are present, mTORC1 directly phosphorylates and suppresses the activity of the kinase complex ULK1-ATG13-FIP200 (unc-51-like kinase 1-autophagy-related 13-focal adhesion kinase familyinteracting protein of 200 kDa [99] [100] [101] ), which is required to induce autophagosome biogenesis 102, 103 . The inhibition of mTORC1, by either starvation or drugs, leads to the activation of ULK1-ATG13-FIP200 and autophagy. Thus, the level of cellular autophagy inversely correlates with mTORC1 activity, and the pharmacological inhibitio n of mTORC1 potently stimulates autophagy.
It was recently shown that the level of amino acids inside the lysosomal lumen controls mTORC1 docking on the lysosomal surface, which is a prerequisite for its activity, and that amino acids must accumulate in the lysosomal lumen in order for mTORC1 to bind and become activated 104 . These observations support the idea that mTORC1 activity is dependent on the lysosome and explains why mTORC1 is reactivated upon the lysosomal degradation of autophagic substrates that occurs during starvation 105 . A recent study demonstrated that an endolysosomal ATP-sensitive Na + -permeable channel, lysoNa ATP , which is located on the lysosomal membrane, also interacts with mTORC1 and participates in nutrient sensing. During starvation, mTORC1 is released from the lysosomal surface, and lysoNa ATP Thus, a complex signalling machinery, which involves mTORC1 as well as additional protein complexes, is located on the lysosomal surface. This machinery, herein referred to as LYNUS (lysosome nutrient sensing), responds to the lysosomal amino acid content and signals the information both to the cytoplasm and the nucleus. The main components of the LYNUS machinery are illustrated in FIG. 2 .
The involvement of the lysosome in nutrient sensing is a new concept that expands our view of this organelle from simply being an effector of cellular clearance to being a sensor and regulator of various cellular functions, including cell cycle progression, growth, macromolecule biosynthesis and autophagy 107 . The recent discovery of a starvation-induced lysosome-to-nucleus signalling mechanism (see below) further supports this concept 108 . Interestingly, autophagic lysosomal reformation (ALR), a recently described evolutionarily conserved process by which nascent lysosomes are formed from autolysosomal membranes, also requires mTORC1 reactivation during prolonged starvation 105, 109, 110 . Furthermore, prolonged starvation also controls lysosomal reformation through the kinase activity of phosphatidylinosit ol 4-kinase IIIβ (PI4KIIIβ) 21 .
Regulation of lysosome function
The recent discovery of a lysosomal gene network and of its master regulator TFEB has revealed that lysosomal function can be coordinated to respond and adapt to environmental cues. The central role of TFEB in regulating lysosomal biogenesis, lysosome-to-nucleus signallin g and lipid catabolism is discussed below.
TFEB regulates lysosomal biogenesis and cellular clearance. Lysosome-mediated cellular clearance processes require the concerted action of hydrolases, the acidification machinery and membrane proteins. The expression and activity of these components must be coordinated This model illustrates how the activity of transcription factor EB (TFEB) is induced by limited nutrient availability and mediates the starvation response by regulating lipid catabolism. In the presence of sufficient nutrients, TFEB interacts with the lysosome nutrient sensing (LYNUS) machinery, which senses lysosomal nutrient levels via the vacuolar ATPase (v-ATPase) complex, and is phosphorylated by mammalian target of rapamycin complex 1 (mTORC1) on the lysosomal surface (1). This keeps TFEB inactive by cytosolic sequestration. During starvation, mTORC1 is released from the LYNUS machinery and becomes inactive. Thus, TFEB can no longer be phosphorylated by mTORC1 and translocates to the nucleus, where it induces its own transcription (2) . Therefore, starvation regulates TFEB activity through a dual mechanism that involves a post-translational modification (that is, phosphorylation) and a transcriptional autoregulatory loop. Once in the nucleus, TFEB regulates the expression of genes involved in the lysosomal-autophagy pathway (3), as well as of PPARα (peroxisome proliferator-activated receptor-α) and PGC1α (PPARγ co-activator 1α) and their target genes (4) . In this way, TFEB controls the starvation response by activating both lipophagy (5) and fatty acid β-oxidation (6). The insert shows the main components of the LYNUS machinery. mTORC1, which includes regulatory proteins associated with mTOR, such as RAPTOR (regulatory-associated protein of mTOR), mLST8 (mammalian lethal with SEC13 protein) and DEPTOR (DEP domain-containing mTOR-interacting protein) 211 , physically interacts with RAG GTPases (RAGA or RAGB and RAGC or RAGD), which activate mTORC1 on the lysosomal surface 212 . A complex known as Ragulator mediates the activation and docking of RAG GTPases to the lysosomal membrane 97, 213 . The small GTPase RAS homologue enriched in brain (RHEB) is also involved in the growth factor-mediated activation of mTORC1 (REFS 214, 215) . The v-ATPase complex functions in amino acid sensing and mediates amino acid-sensitive interactions between RAG GTPases and Ragulator, which is the initial step in lysosomal signalling 104 . The endolysosomal ATP-sensitive Na + -permeable channel (lysoNa ATP ), which comprises the subunits two pore calcium channel 1 (TPC1) and TPC2, is located on the lysosomal membrane, and it has recently been shown to interact with mTORC1 and to participate in nutrient sensing 106 . The nature of the interaction between lysoNa ATP and mTORC1 is unknown but seems to be independent form other components of the LYNUS machinery as well as TFEB and its interacting proteins (see main text). 
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Regulation of lysosomal gene expression
to allow optimal lysosomal function in different physiological and pathological conditions, such as growth, starvation, infection and the pathological accumulation of lysosomal substrates. This concept of lysosomal adaptation has emerged only recently, as little attention was given to the study of the transcriptional regulation of the genes encoding lysosomal proteins. The recent discovery of a lysosomal gene network -the coordinated lysosomal expression and regulation (CLEAR) network -and of its master regulator TFEB (a member of the MITF (microphthalmia-associated transcription factor) subfamily of transcription factors 111 that was previously implicated in a specific type of chromosomal translocation associated with renal carcinoma 112 ) provides experimental evidence that lysosomal function is globally controlled 12 . The systems biology approach used to identify the CLEAR network is summarized in BOX 2.
Consistent with its role as a modulator of the CLEAR network, TFEB positively regulates the expression of lysosomal genes, controls the number of lysosomes and promotes the ability of cells to degrade lysosomal substrates 12, 113 . Further unbiased genomic and expression analyses, together with deep sequencing of TFEB chromatin-immunoprecipitates, allowed a more detailed analysis of the CLEAR network and revealed that TFEB is a central regulator of cellular degradative pathways 114 . Specifically, it activates the transcription of genes that encode proteins involved in several aspects of cellular clearance, such as lysosomal biogenesis, autophagy, exocytosis, endocytosis and additional lysosomeassociate d processes, such as phagocytosis, the immune response and lipid catabolism. Interestingly, many nonlysosoma l proteins involved in the degradation of known autophagy substrates were also found to be members of this network 114 . These observations suggested that TFEB also regulates autophagy 114 . Indeed, TFEB overexpression in cultured cells significantly increased the number of autophagosomes and enhanced lysosomeautophagosome fusion and the degradation of longlived proteins that are known autophagy substrates 13 . Consistently, viral-mediated overexpression of TFEB in the liver induced autophagy 13 . Thus, although the delivery of autophagy substrates to the lysosome and their degradation by lysosomal enzymes are distinct cellular processes, they are mechanistically linked by a common transcriptional regulatory programme 13, 115 . Other examples of transcription factors that regulate autophagy have been reported [116] [117] [118] [119] [120] [121] [122] [123] . The forkhead box O (FOXO) transcription factor family (including FOXO1, FOXO3, FOXO4 and FOXO6) is negatively regulated by the insulin pathway in an AKT-dependent manner. FOXO proteins are well conserved and have
Box 2 | The identification of the CLEAR gene network
Gene networks control several aspects of cellular function and metabolism, such as the coordination of the cellular response to environmental conditions. In specialized organelles, this coordination is facilitated by compartmentalization. A systems biology approach was used to test the hypothesis that lysosomal genes are co-expressed, regulated by common factors and able to respond to similar environmental cues (see the figure) . The expression behaviour of genes encoding lysosomal proteins was analysed using publicly available microarray data. This analysis revealed that lysosomal genes have a statistically significant tendency to be co-expressed in various different tissues and cell types as well as under different conditions 12 . Subsequently, pattern discovery analysis revealed the presence of a palindromic 10-base site in the promoters of known lysosomal genes. This sequence was previously identified as a specific version of a known target site for basic-helix-loop-helix (bHLH) transcription factors, also known as an E-box. Thus, these two independent approaches, namely co-expression and promoter analyses, identified a new gene network which was named CLEAR (coordinated lysosomal expression and regulation). Further studies demonstrated that transcription factor EB (TFEB), which belongs to the MITF (microphthalmia-associated transcription factor) subfamily of bHLH transcription factors, binds to CLEAR target sites in the promoters of lysosomal genes and positively regulates their expression, acting as a master regulator of the CLEAR network 12 .
Bits, universal measurement of sequence conservation.
Wolman's disease
An early-onset fulminant disorder of infancy with substantial infiltration of several organs, including the spleen and the liver, by macrophages filled with cholesteryl esters and triglycerides. It is caused by mutations in the gene encoding lipase A. a crucial role in many cellular processes, including in the regulation of autophagy 120, 124 . FOXO3 is activated during fasting and mediates the transcription of many genes that directly and indirectly regulate autophagy induction 121, 122 . Thus, FOXO3 regulation and function are very similar to those of TFEB, suggesting possible interactions between the two pathways. Indeed, FOXO3A overexpression increases cellular Gln levels and inhibits mTORC1 activity, leading to TFEB activation and the coordinated transcriptional activation of lysosomal biogenesis and autophagy 119 . Another transcription factor that regulates autophagy is ZKSCAN3, which belongs to the family of zinc-fing er transcription factors that contain KRAB and SCAN domains and has recently been identified as a repressor of autophagy 123 . When ZKSCAN3 is silenced, cellular senescence and autophagy are promoted. By contrast, when ZKSCAN3 is overexpressed, autophagy is suppressed in diverse cellular models. ZKSCAN3 was also shown to negatively regulate the expression of genes involved in autophagy and lysosome biogenesis and function. Interestingly, starvation induces the cytoplasmic accumulation of ZKSCAN3 and thereby inhibits its activity. Conversely, nutrient availability promotes ZKSCAN3 nuclear translocation in an mTOR-dependent manner 123 . In conclusion, it seems that TFEB and ZKSCAN3 have opposing functions in regulating lysosome biogenesis and autophagy in response to cellular needs. It will be interesting to determine whether these two transcription factors work in conjunction with each other.
TFEB conveys signals from the lysosome to the nucleus.
Transcriptional mechanisms that control crucial cell ular functions should respond to environmental cues. Under basal conditions in most cell types, TFEB is located in the cytoplasm. However, under specific conditions, such as starvation or lysosomal dysfunction, TFEB rapidly translocates to the nucleus 12, 13 . This process is controlled by the TFEB phosphorylation status; phosphorylated TFEB is located predominantly in the cytoplasm, whereas the dephosphorylated form is found in the nucleus 13 . Phosphoproteomic studies identified at least ten different phosphorylation sites in the TFEB protein, suggesting a complex regulatory mechanism 125 . At least three different kinases have been shown to phosphorylate TFEB: ERK2 (REFS 13,126); mTORC1 (REFS 108,126-129), and protein kinase Cβ (PKCβ) 95 . Phosphorylation of Ser142 by ERK2 and of both Ser142 and Ser211 by mTORC1 is crucial in determining the subcellular localization of TFEB. Mutation of either or both of these Ser residues to Ala results in the constitutive nuclear localization of TFEB 13, 108, 127, 129 . By contrast, during osteoclast differentiation, PKCβ-induced phosphorylation of three Ser residues located in the final 15 carboxy-terminal amino acids of TFEB stabilizes the protein and increases its activity 95 . Interestingly, cytoplasmic TFEB is located both in the cytosol and on the lysosomal surface, where it interacts with mTORC1 and the LYNUS machinery 108, 130 (FIG. 2) .
This observation suggests a mechanism by which the lysosome regulates its own biogenesis by controlling TFEB subcellular localization. Cellular conditions that lead to mTORC1 inactivation, such as stress, starvation and lysosomal inhibition, induce TFEB nuclear translocation and thus activate the lysosomal system 108, 127, 129 . In addition, several isoforms of the 14-3-3 protein family have an important role in controlling TFEB sub cellular localization by retaining phosphorylated TFEB in the cytoplasm 127,129 . More recently, TFEB was shown to interact with active RAG GTPases 130 . This interaction promotes the lysosomal localization of TFEB and its mTORC1-dependent phosphorylation 130 . Interestingly, other members of the basic-helix-loop-helix (bHLH) family of transcription factors, such as MITF and TFE3, the sequences of which are closely related to TFEB, seem to be regulated by a similar mechanism 129, 130 . It will be interesting to investigate whether other additional mTOR-independent mechanisms also regulate the nuclear translocation of TFEB.
Recent data indicate that cellular nutrient levels regulate TFEB also at the transcriptional level. The absence of serum and amino acids from the cell culture medium induces TFEB expression, whereas their re-addition in activates this transcription factor. Similarly, depriving mice of food for 24 hours induces TFEB expression in multiple tissues 131 . Interestingly, the trans criptional response of TFEB to nutrients is mediated by an autoregulatory feedback loop in which TFEB binds to its own promoter in a starvation-dependent manner and induces its own expression 131 . Thus, the regulation of TFEB activity by nutrients involves a rapid, p hosphorylationdependent post-transcriptional switch, which is respons ible for the nuclear translocation of TFEB, and a transcriptional autoregulatory component, which allows for a slower, more sustained response. This complex regulation mediates the cellular starvation response by inducing lipid catabolism 131 (see below). In conclusion, TFEB participates in a lysosometo-nucleus signalling mechanism that conveys information on the lysosomal status to the nucleus to trigger a transcriptional response. This crosstalk between the lysosome and the nucleus controls cellular clearance and energy metabolism. A proposed model of TFEB regulatio n by nutrients is illustrated in FIG. 2. TFEB regulates lipid catabolism. Autophagy has a central role in lipid metabolism by shuttling lipid droplets to lysosomes, where they are hydrolysed into free fatty acids (FFAs) and glycerol. This process, called macrolipophagy 132, 133 , indicates the presence of a tight relationship between intracellular lipid metabolism and lysosomes. Interestingly, excessive lipid overload may in turn inhibit autophagy. This could be caused by either an alteration of the composition of the lysosomal membrane, rendering it less prone to fusion with autophagosomes 134, 135 , or by the downregulation of autophagy genes 136 . Restoring liver autophagy ameliorates the metabolic phenotype of genetically induced obese mice (Ob/ Ob), suggesting that enhancing lysosomal function may be a possible therapeutic strategy for the treatment of obesity 136 . Interestingly, lysosomal dysfunction was associated with an altered energy balance in mouse models of LSDs 137 . In addition, in Wolman's disease, the Multiple sulphatase deficiency (MSD). An autosomal recessive inherited disease that is caused by mutations in the sulphatasemodifying factor 1 (SUMF1) gene.
Mucopolysaccharidosis (MPS).
A metabolic disorder that is caused by the absence or malfunctioning of lysosomal enzymes needed to break down molecules.
deficiency of lysosomal acid lipase leads to a severe intracellular fat accumulation 138 . These studies suggest that the regulation of the lysosomal and autophagic pathways may have an effect on cell ular lipid metabolism. Indeed, TFEB was found to regulate liver lipid metabolism 131 . Transcriptome analysis in the mouse liver after viral-mediated TFEB over expression revealed that this transcription factor positively regulates the expression of genes involved in several steps of lipid breakdown, such as lipophagy, fatty acid oxidation and ketogenesis. Interestingly, PPARα (peroxisome proliferator-activated receptor-α) and PGC1α (PPARγ co-activato r 1α), which are key regulators of lipid metabolism in response to starvation 131, 139 , are significantly induced by TFEB. In addition, TFEB was shown to directly bind to the PGC1α promoter in a starvation-sensitive manner 131 . Remarkably, whereas liver-specific TFEB knockout caused defective lipid degradation during starvation, TFEB overexpression enhanced liver fat catabolism and prevented diet-induced obesity 131 . Thus, TFEB controls the cellular response to nutrient levels and induces a metabolic switch that allows the organism to generate energy from stored lipids. These observations shed new light on the role of the lysosome in cellular energy metabolism and the mechanisms underlying obesity and metabolic syndrome. A proposed model for the role of TFEB in lipid catabolism is illustrated in FIG. 2. TFEB regulation and function are evolutionarily conserved. The Caenorhabditis elegans genome encodes a single homologue of TFEB, HLH-30, which is a transcription factor that recognizes a DNA motif similar to the CLEAR motif and drives the transcription of metabolic genes 140 . HLH-30 acts in a similar manner to TFEB during C. elegans starvation. Hlh-30 mRNA progressively accumulates during starvation and rapidly decreases after the re-addition of food, as is the case with mammalian TFEB 131, 141 . HLH-30 also responds to starvation in a manner similar to its human counterpart, as it can be detected mainly in the cytoplasm of well-fed C. elegans and predominantly in the nucleus of fasting animals 141 . The autoregulatory loop that regulates TFEB transcription is conserved in C. elegans 131 . Interestingly, HLH-30 activity is required to mobilize cytosolic lipids in fasting nematodes. Starved hlh-30 mutants failed to mobilize lipids as promptly as wild-type animals 131, 141 , indicating that HLH-30 is required for C. elegans to efficiently use lipid stores during periods of starvation. HLH-30 is essential for the induction of lipid catabolism genes such as lipase 2, lipase 3 and lipase 5 during fasting 141 , and the induction of these genes is greatly compromised in starved nematodes when hlh-30 is deleted 131 . Notably, starved hlh-30 mutants fail to mobilize their lipid stores due to a severe transcriptional response defect.
In wild-type C. elegans, starvation results in lifespan extension 142 . However, loss of hlh-30 was shown to result in the abrogation of starvation-induced lifespan extension 131, 141 , suggesting an important role for HLH-30 (and possibly TFEB) in longevity. Consistent with this, nematodes that are mutant for daf-2, which encodes the insulin-like growth factor 1 (IGF-1) receptor, have an increased lifespan, and it has been shown that they exhibit upregulated autophagy 143 . In conclusion, HLH-30 and mouse TFEB share evolutionarily conserved functions in the adaptation of organisms to starvation. As observed for mammalian TFEB, hlh-30 expression is autoregulated, required for lipid mobilization and is essential for the starvation response. The C. elegans model will be very useful for studying, in more detail, the potential role of TFEB in cell survival and ageing in different conditions, considering that TFEB total loss of function is embryonic lethal in mice 144 . The striking conservation of TFEB function in C. elegans suggests that this regulatory mechanism evolved early to facilitate organismal adaptation to challengin g nutritional conditions 131, 141 .
Lysosomal dysfunction and human disease
Lysosomal dysfunction has been associated with several human diseases, as well as with the process of ageing, which may be associated with a decline in lysosomal function and a progressive accumulation of intra cellular material (for example, lipofuscin and ubiquitin) 145 . Indeed, enhancement of the autophagic-lysosomal pathway seems to be an important determinant of the anti-ageing effect of caloric restriction 146 . The identification of factors that regulate lysosomal biogenesis and function, such as TFEB, should pave the way to the development of novel therapeutics for diseases in which lysosoma l dysfunction is aberrant.
Lysosomal dysfunction in LSDs and neurodegenerativ e diseases. For more than three centuries, it has been known that genetic defects in specific lysosomal components lead to the accumulation of substrates that are not degraded in the lysosomal lumen, followed by progressive lysosomal dysfunction in several tissues and organs. These disorders are known as LSDs. The classification of LSDs and their clinical features has been reviewed in detail in several recent articles [147] [148] [149] [150] [151] [152] . Although these diseases were among the first for which both the biochemical and the molecular basis were recognized, the mechanisms by which the storage of material that has not been degraded in lysosomes translates into cellular and tissue dysfunction and clinical symptoms have yet to be fully elucidated. The main mechanisms that have been identified so far are summarized in BOX 3. A global impairment of lysosomal function has an important role in the pathogenesis of several LSDs, because a deficiency in individual lysosomal proteins can have broad consequences on the basic functions of lysosomes 147 . In particular, several studies have demonstrated an impairment of the autophagic pathway in LSDs 147, [153] [154] [155] [156] [157] . This results in the secondary accumulation of autophagy substrates, such as dysfunctional mitochondria and polyubiquitylated proteins, which have a crucial role in disease pathogenesis 157 . A block of autophagy in LSDs may be caused by a defect in the fusion between lysosomes and autophagosomes, as observed in multiple sulphatase deficiency (MSD) and mucopolysaccharidosis type IIIA (MPSIIIA), which may be caused by abnormalities in membrane lipid composition and SNARE protei n distribution 156 .
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Gaucher's disease
An autosomal recessive lysosomal storage disorder due to the deficient activity of β-glucocerebrosidase.
Current therapeutic strategies for LSDs are aimed at either restoring or replacing the activity of defective lysosomal enzymes, and they involve molecular chaperones, enzyme replacement or viral-mediated gene therapy 158 . Inhibition of substrate synthesis is another available thera peutic option for some LSDs 158 . These strategies, however, have limitations, such as the difficulty of targeting the enzyme, or the gene, to the required sites in the body. For instance, a major hurdle for delivering therapies to the brain is the difficulty that these enzymes encounter in crossing the blood-brain barrier. Considering that LSDs include over 60 different diseases and that in most cases each therapy is strictly disease-specific, the overall costs of preclinical studies and clinical trials will be extremely high.
Accumulating evidence indicates that lysosomal and autophagy dysfunction is one of the main mechanisms underlying common neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease and Huntington's disease 159, 160 (FIG. 3) . Mutated aggregate-prone protein s that cause neurodegenerative diseases, such as expanded huntingtin (HTT) in Huntington's disease and mutated α-synuclein in Parkinson's disease, are cleared by boosting the lysosomal-autophagic pathway [161] [162] [163] .
In addition, aggregate-prone proteins may in turn affect the efficiency of autophagy by inhibiting cargo recognitio n by autophagosomes 164, 165 . Mutations in genes encoding essential components of the endolysosomal-autophagic pathway have also been described in several neurodegenerative diseases. A significant number of patients with Parkinson's diseas e, particularly among Ashkenazi Jews 166 , are hetero zygous for mutations in the gene encoding the lysosomal enzyme β-glucocerebrosidase 167 . Homozygous mutations in the same gene cause Gaucher's disease, a neurodegenerative LSD 168 . It has been proposed that lower levels of β-glucocerebrosidase lead to an increased accumulation of glucosylceramide in the lysosome, and this in turn accelerates the synthesis and stabilization of soluble α-synuclein oligomers that eventually convert into amyloid fibrils. Furthermore, the accumulation of α-synuclein also blocks the trafficking of newly synthesized β-glucocerebrosidase to the lysosome and thus further amplifies glucosylceramide accumulation 169 . In addition, mutations in ATPase type 13A2 (ATP13A2), a component of the lysosomal acidification machinery, were found in patients with hereditary parkinsonism 170 and are associated with lysosomal dysfunction, defective
Box 3 | Mechanisms of lysosomal storage diseases (LSDs)
LSDs are a group of rare and recessively inherited metabolic dysfunctions with an overall incidence of 1 in 5000. LSDs are caused by mutations of genes encoding proteins that localize to the lysosomal lumen, lysosomal membrane or other cellular compartments that contribute to lysosomal function. These disorders are characterized by the progressive accumulation of material that has not been degraded in the lysosomes of most cells and tissues. Approximately 60 different types of LSDs have been recognized. Historically, LSDs have been classified on the basis of the type of material that accumulates in the lysosomes, such as mucopolysaccharides, sphingolipids, glycoproteins, glycogen and lipofuscins. LSDs often show a multisystemic phenotype that is associated with severe neurodegeneration, mental decline, cognitive problems and behavioural abnormalities. Other tissues that are commonly affected are bone and muscle. Cell and tissue pathology are the result of a complex series of pathogenic cascades that occur downstream of lysosomal dysfunction. The figure illustrates the main steps underlying LSD pathogenesis. Mutations in genes that are important for lysosomal function result in the accumulation of specific substrates that have not been degraded in the lysosome (primary storage). This leads to the accumulation of additional lysosomal substrates (secondary storage) due to a blockage in lysosomal trafficking. Excessive lysosomal storage has a broad impact on lysosomal function by causing defects in Ca 2+ homeostasis, signalling abnormalities and lysosomal membrane permeabilization. In addition, lysosomal dysfunction is associated with autophagy impairment, due to defective fusion between lysosomes and autophagosomes. This causes the accumulation of autophagic substrates such as aggregate-prone proteins and dysfunctional mitochondria (tertiary storage), which contributes to neurodegeneration. GAGs, glycosaminoglycans.
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Mutation of genes involved in the endolysosomal pathway 
Charcot-Marie-Tooth type 2B
Autosomal dominant peripheral sensory neuropathy due to mutations in the late endosomal small GTPase RAB7.
Neuronal ceroid lipofuscinosis
A clinically and genetically heterogeneous group of neurodegenerative disorders that are characterized by the intracellular accumulation of autofluorescent lipopigment storage material.
Pompe's disease
An autosomal recessive inherited disease, also known as glycogen storage disease II. This prototypic lysosomal storage disease is caused by mutations in the gene encoding acid α-1,4-glucosidase.
clearance of autophagosomes and accumulation of α-synuclein 171 . Similarly, mutations in the genes encoding PINK (PTEN-induced putative kinase) and PARKIN (Parkinson's disease protein) are associated with the defective clearance of mitochondria via an organel lespecific type of autophagy known as mitophagy, leading to Parkinson's disease [172] [173] [174] [175] . Parkinson's disease was also observed in patients carrying mutations in the VPS35 (vacuolar protein sorting 35), which encodes an endosomal protein involved in the retrograde transport between endosomes and the TGN 176, 177 . Lysosomal and autophagy dysfunction have also been identified in patients with Alzheimer's disease carrying mutations in presenilin 1 (PSEN1) 178 . At least two different mechanisms, one involving a defect in lysosomal acidification machinery 178 and the other a defect in lysosomal Ca +2 homeostasis 179 , have been proposed to explain lysosomal dysfunction in these patients. Additional examples of neurodegenerative diseases that are caused by mutations of proteins involved in endosome and lysosome maturation include fronto-temporal dementia and Charcot-Marie-Tooth type 2B, which are due to mutations in charged multivesicular body protein 2B (CHMP2B) 180 and RAB7 (REF. 181 ), respectively. Of note, a mutation in the autophagic protein WD repeat domain 45 (WDR45) has been recently associated with SENDA (static encephalopathy of childhood with neurodegeneration in adulthood), a neurodegenerative disease characterized by iron accumulation in the brain 182 .
TFEB activation as a potential therapy. The similarities between the mechanisms that lead to LSDs and common neurodegenerative diseases suggest that therapeutic strategies aimed at rescuing and/or enhancing lysosomal and autophagic function may have an impact on both types of diseases. Several attempts have been made to treat animal models of neurodegenerative diseases by enhancing the lysosomal-autophagic pathway 160, [183] [184] [185] [186] [187] [188] [189] . An appealing therapeutic perspective, which has become available since the recent discovery of TFEB, would be to enhance cellular clearance by inducing TFEB function. Preliminary evidence showed that cells with enhanced TFEB levels displayed a faster rate of glycosaminoglycans (GAGs) clearance compared with control cells 12 . TFEB over expression also resulted in a striking reduction of GAGs and cellular vacuolization in glia-differentiated neuronal stem cells (NSCs) that were isolated from mouse models of MSD and MPSIIIA, two severe types of LSD 86 . Similar results were obtained using this approach in cells from patients with other types of LSDs and/or the respective mouse models, including neuronal ceroid lipofuscinosis type 3 (due to mutations of the CLN3 gene; also known as Batten disease) and Pompe's disease 86 . In all cases, TFEB overexpression led to the clearance of the storage material within cells. TFEBmediated cellular clearance was also observed in vivo in mouse models of MSD and Pompe's disease upon viralmediated TFEB gene transfer 86, 190 . TFEB overexpression in a mouse model of Pompe's diseas e reduced glycogen load and lysosomal size, improved autophagosome processing and alleviated the accumulation of autophagic vacuoles in muscle from affected mice. Interestingly, the clearance effect of TFEB was found to be dependent on the autophagy pathway, and in the muscl e, TFEB was shown to induce exocytosis of autophagolysosomes (also known as autolysosomes) via their fusion with the plasma membrane 190 . Notably, TFEB was also used as a tool to promote cellular clearance in common neurodegenerative diseases. TFEB gene delivery in a mouse model of Parkinson's disease ameliorated tissue pathology 191 . In a recent study, TFEB was identified as the main mediator of the ability of PGC1α to promote cell ular clearance and to decrease neurotoxicity in a mouse model of Huntington's disease 192 . Finally, TFEB overexpression in the liver of mice carrying a mutated form of α1-antitrypsin resulted in the clearance of this mutated protein and rescued the liver fibrosis phenotype 193 . The mechanism by which TFEB promotes the clearance of storage material needs to be further elucidated. TFEB induction rescues lysosomal storage in LSDs in spite of a complete deficiency of one or more lysosomal enzymes. A prevailing mechanism in this case may be the activation of lysosomal exocytosis, by which the stored material may be secreted from cells upon TFEB overexpression. However, in general, it is possible that TFEBmediated cellular clearance is the result of the combined effects of lysosomal biogenesis, autophagy and lysosomal exocytosis (FIG. 4) . The possibility of pharmacologically 
Cellular clearance
Lysosome biogenesis modulating lysosomal function, for example by inhibiting TFEB phosphorylation or by increasing TFEB dephosphorylation, represents an attractive therapeutic strategy to promote cellular clearance in all of the above-mentioned diseases. Therefore, drug screening approaches aimed at identifying molecules that promote TFEB nuclear translocation present an interesting path forward. However, careful, long-term studies evaluating the potential side effects will be required. Pulsatile treatments that can increase TFEB activity for only limited periods of time may be the best option for diseases in which the accumulation of storage material takes a long time. At this stage, it is too early to determine whether TFEB induction will be a viable thera peutic option for LSDs or for other diseases. However, the broad range of diseases that might be treated by this therapeutic strateg y make it a very appealing avenue.
Conclusions and future perspectives
The emerging role of the lysosome in important processes, such as nutrient sensing, signalling and metabolism, requires further investigation -what we know today is just the tip of the iceberg. Systematic approaches, such as transcriptomics, proteomics and metabolomics, coupled with the power of systems biology, will be particularly important for identifying all the components of the lysosome and understanding the role of the greater lysosomal system 152 . These approaches should be complemented by in vivo imaging and intravital microscopy, which allow the visualization of lysosomes in the context of a living organism and in specific physiological or pathological conditions. Interdisciplinary approaches will also allow us to answer intriguing questions. How does lysosome number, size and content vary in different cell types, in different tissues or in different individuals? Do different types of lysozymes exist with specialized roles? To what extent do environmental or pathological conditions influence the composition, function or identity of lysosomes? What is the physiological role of lysosomal signalling and its involvement in human disease?
Besides the involvement in neurodegenerative diseases, the role of the lysosome in other pathological processes, such as abnormalities of lipid metabolism, infections and even ageing, is still largely unexplored. Transcriptomic and proteomic analysis of patientderived tissues and whole genome and exome sequencing of the DNA of patients may lead to the discovery of lysosomal variation as a predisposing factor for additional human diseases. Furthermore, studying lysosomal function in various disease processes will affect the development of novel therapeutic strategies. Moreover, the development of high-content screening approaches will pave the way for the identification of novel compounds that are able to modulate lysosomal function, which could in turn be used as effective drugs to promot e cellular clearance. Transcription factor EB (TFEB) controls lysosomal biogenesis by regulating the level of lysosomal enzymes, lysosomal acidification and the number of lysosomes. TFEB also controls autophagy by regulating the number of autophagosomes and the fusion between autophagosomes and lysosomes. Finally, TFEB regulates the docking and fusion of lysosomes to the plasma membrane in the process of lysosomal exocytosis. The concerted action of these three processes leads to cellular clearance.
